Mediar Therapeutics, a Cambridge, MA-based biotechnology company, raised $105M in funding.
The round was led by Novartis Venture Fund and Sofinnova Partners with participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli Lilly & Company, Ono Venture Investment and Mass General Brigham Ventures.